Holen Sie sich die Stockscreener-App
12.56
31.11%
2.98
Handel nachbörslich:
13.18
0.62
+4.94%
Schlusskurs vom Vortag:
$9.58
Offen:
$9.58
24-Stunden-Volumen:
93,812
Relative Volume:
13.95
Marktkapitalisierung:
$254.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-24.11%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.08
$15.50
1-Wochen-Bereich:
$6.10
$16.00
52-Wochen-Spanne:
$6.10
$21.00
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
Firmenname
Neonc Technologies Holdings Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie NTHI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
12.56 | 254.03M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Neonc Technologies Holdings Inc Aktie (NTHI) Neueste Nachrichten
Neonc Technologies appoints new accounting firm By Investing.com - Investing.com Canada
Neonc Technologies appoints new accounting firm - Investing.com India
NeOnc Technologies Partners with CBCC for Clinical Expansion - TipRanks
NeOnc Technologies receives RPDD for NEO100 - TipRanks
NeOnc Technologies Holdings: New IPO gets a Rare Pediatric Disease Designation and a 37.92% Jump in the Market - RagingBull
NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation - MarketScreener
NeOnc Falls Despite FDA Nod - Baystreet.ca
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric - GlobeNewswire
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - Yahoo Finance
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - The Manila Times
NeOnc Technologies Expands Global Clinical Trial Network - GlobeNewswire
NeOnc Technologies Holdings, Inc. Rings the Opening Bell - Nasdaq
NTHI IPO NewsBiotech NeOnc Technologies' share registration declared effective ahead of Nasdaq direct listing - renaissancecapital.com
NeOnc Technologies Holdings Announces Effectiveness of - GlobeNewswire
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market - Yahoo Finance
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors - Yahoo Finance
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors - GlobeNewswire
NeOnc Technologies Holdings, Inc. Appoints Dr. Steven L. Giannotta to Board of Directors - Nasdaq
Nasdaq’s opening bell will ring for USC research startup NeOnc - USC Today
Planet TV Studios Airing “New Frontiers” Episode on NeOnc Technologies Holdings, Inc. – Saturday, March 15, - EIN News
Expanding horizons: NeOnc Technologies’ bold vision - The Business Journals
NeOnc Technologies plans to go public through direct listing - AlphaStreet
NeOnc Technologies has another go at a Nasdaq listing - pharmaphorum
Cancer Drug Co. Revives Bid To Go Public Via Direct Listing - Law360
NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024 - GlobeNewswire
A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets - MedCity News
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate - GlobeNewswire
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors - BioSpace
NeOnc Technologies Receives FDA Approval to Expand - GlobeNewswire
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status - GlobeNewswire
NeOnc Technologies Holdings: NTHI IPO, Health CarePhase 2 biotech developing intranasal and oral therapies for brain cancer. - renaissancecapital.com
NeOnc Technologies Holdings Receives FDA Authorization to - GlobeNewswire
NeOnc Technologies Appoints Sidra Medicine CEO and Forbes - GlobeNewswire
NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’ - GlobeNewswire
Finanzdaten der Neonc Technologies Holdings Inc-Aktie (NTHI)
Es liegen keine Finanzdaten für Neonc Technologies Holdings Inc (NTHI) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):